CASE DETAILS: According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback